Hepatic Surgery IV, Shanghai Eastern Hepatobiliary Surgery Hospital, The Third Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
Ultrasound Diagnosis, PLA Naval Medical Center, Shanghai 200437, China.
World J Gastroenterol. 2024 Jun 14;30(22):2881-2892. doi: 10.3748/wjg.v30.i22.2881.
Posthepatectomy liver failure (PHLF) is one of the most important causes of death following liver resection. Heparin, an established anticoagulant, can protect liver function through a number of mechanisms, and thus, prevent liver failure.
To look at the safety and efficacy of heparin in preventing hepatic dysfunction after hepatectomy.
The data was extracted from Multiparameter Intelligent Monitoring in Intensive Care III (MIMIC-III) v1. 4 pinpointed patients who had undergone hepatectomy for liver cancer, subdividing them into two cohorts: Those who were injected with heparin and those who were not. The statistical evaluations used were unpaired -tests, Mann-Whitney tests, chi-square tests, and Fisher's exact tests to assess the effect of heparin administration on PHLF, duration of intensive care unit (ICU) stay, need for mechanical ventilation, use of continuous renal replacement therapy (CRRT), incidence of hypoxemia, development of acute kidney injury, and ICU mortality. Logistic regression was utilized to analyze the factors related to PHLF, with propensity score matching (PSM) aiming to balance the preoperative disparities between the two groups.
In this study, 1388 patients who underwent liver cancer hepatectomy were analyzed. PSM yielded 213 matched pairs from the heparin-treated and control groups. Initial univariate analyses indicated that heparin potentially reduces the risk of PHLF in both matched and unmatched samples. Further analysis in the matched cohorts confirmed a significant association, with heparin reducing the risk of PHLF (odds ratio: 0.518; 95% confidence interval: 0.295-0.910; = 0.022). Additionally, heparin treatment correlated with improved short-term postoperative outcomes such as reduced ICU stay durations, diminished requirements for respiratory support and CRRT, and lower incidences of hypoxemia and ICU mortality.
Liver failure is an important hazard following hepatic surgery. During ICU care heparin administration has been proved to decrease the occurrence of hepatectomy induced liver failure. This indicates that heparin may provide a hopeful option for controlling PHLF.
肝切除术后肝功能衰竭(PHLF)是肝脏切除术后死亡的最重要原因之一。肝素是一种已被确立的抗凝剂,通过多种机制可以保护肝功能,从而预防肝功能衰竭。
观察肝素预防肝切除术后肝功能障碍的安全性和有效性。
从 Multiparameter Intelligent Monitoring in Intensive Care III(MIMIC-III)v1.4 中提取数据,确定接受肝癌切除术的患者,将他们分为两组:接受肝素注射的患者和未接受肝素注射的患者。使用配对 t 检验、Mann-Whitney 检验、卡方检验和 Fisher 精确检验评估肝素给药对 PHLF、重症监护病房(ICU)住院时间、机械通气需求、持续肾脏替代治疗(CRRT)的使用、低氧血症的发生率、急性肾损伤的发展和 ICU 死亡率的影响。采用 logistic 回归分析与 PHLF 相关的因素,采用倾向评分匹配(PSM)平衡两组术前差异。
本研究共分析了 1388 例接受肝癌切除术的患者。PSM 从肝素治疗组和对照组中产生了 213 对匹配对。初步单变量分析表明,肝素在匹配和非匹配样本中均降低了 PHLF 的风险。在匹配队列中的进一步分析证实了肝素的显著相关性,肝素降低了 PHLF 的风险(比值比:0.518;95%置信区间:0.295-0.910;P=0.022)。此外,肝素治疗与改善短期术后结局相关,如 ICU 住院时间缩短、呼吸支持和 CRRT 的需求减少、低氧血症和 ICU 死亡率降低。
肝功能衰竭是肝手术后的一个重要危险。在 ICU 护理中,肝素的给药已被证明可降低肝切除术后肝衰竭的发生。这表明肝素可能为控制 PHLF 提供了一种有希望的选择。